Drugs / GSK3390107A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02548078 | Nov 2015 → May 2017 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3390107A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02548078 ↗ |
| Known as | ChAd3-EBO-Z | “GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)” NCT02548078 ↗ |
| Modality | Vaccine | “Zaire Ebola glycoprotein vaccine” PMID 32199492 ↗ Mar 2020 |
| Route | Intramuscular | “A single dose administered intramuscular” NCT02548078 ↗ |